Adaptimmune Therapeutics: A Little More Patience May Be Profitable

Avisol Capital Partners
Investing Group Leader

Summary

  • I must say up front that I do not expect ADAP to make me a profit in the next 12 months because of the poor market conditions.
  • However, I still like the science and am holding on to a small position for the longer term.
  • ADAP has a BLA filing in 2022.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Amazing Meili Snow mountain and mountain range at Yunnan, China

primeimages/E+ via Getty Images

I haven't covered Adaptimmune Therapeutics (NASDAQ:ADAP) since June, and the stock has been cut in half by this terrible market. Adaptimmune is a leader in TCR therapies, however, due to whatever reason, it has not been able to perform too

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-


Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 



This article was written by

Avisol Capital Partners
18.25K Followers

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ADAP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About ADAP Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ADAP

Related Stocks

SymbolLast Price% Chg
ADAP
--
Compare

Trending Analysis

Trending News